Hot Electric Utility Stocks To Buy For 2014

This has been an interesting year in the stock market.

As the market has been lifted to all-time highs by an accommodative monetary policy and an economy starting to fire on all cylinders, long-term investors have profited handsomely during the first half of the year. A pullback in August led the Dow Jones Industrial Average to drop nearly 1,000 points before stabilizing in the 14,800 range. Despite this setback, stocks are still showing signs of strength that should last for the rest of the year.  

But the fuel powering the stock market has its drawbacks: Low interest rates and accommodative policy have sent yields to ultra-low levels while boosting stocks. In fact, income investors have become so frustrated by the lack of yield that this year's investing theme can be summed up in four words: the search for yield.

Top Stocks To Watch For 2015: Carrefour SA (CRERF)

Carrefour SA is a France-based company that is primarily engaged in retail distribution sector. The Company operates a network of hypermarkets, supermarkets, hard discount stores, convenience stores and cash-and-carry outlets and offers e-commerce services. The Company's hypermarkets named Carrefour offer a range of food and non-food products. Carrefour SA�� hypermarkets, supermarkets and convenience stores are operating under the Carrefour city, Carrefour contact, Carrefour express, 8aHuit, Shopi, Marche Plus, Proxi banners and cash & carry stores are operating under the Promocash banner, which primarily offer food, clothing and household goods, among others. The Company operates in mainland France and French overseas territories, as well as in Europe, Asia, Latin America, North Africa and the Middle East through a network of consolidated and franchised stores, and stores that Carrefour SA runs with partner companies. In January 2014, it acquired 129 convenience stores. Advisors' Opinion:

• [By Sophia Yan]

  Carrefour (CRERF) has also shuttered many stores, and is reported to be exploring a sale of its China and Taiwan businesses.

  Hypermarkets -- big box stores that combine supermarkets and department stores -- first opened up in China's largest cities over a decade ago. And it's no wonder companies such as Wal-Mart have been keen to get a slice of the market.

Hot Electric Utility Stocks To Buy For 2014: Advanced Cell Technology, Inc.(ACTC)

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company?s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company?s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it deve lops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.

Advisors' Opinion:

• [By John Udovich]

  As the the year comes to end, there is still a steady flow of interesting news coming from small cap biotech stocks like Organovo Holdings Inc (NYSEMKT: ONVO), Advanced Cell Technology, Inc (OTCMKTS: ACTC) and TNI BioTech (OTCMKTS: TNIB)�plus still largely private biotech companies like Genocea Biosciences (NASDAQ: GNCA), Retrophin (OTCMKTS: RTRX), Auspex Pharmaceuticals (NASDAQ: ASPX) and GlycoMimetics (NASDAQ: GLYC) who have filed to become the next potentially hot biotech IPOs���presumably some time early�next year. Just consider the following biotech news:

• [By CRWE]

  Today, ACTC has shed (-1.05%) down -0.0008 at $.0751 with 2,338,132 shares in play thus far (ref. google finance Delayed: 11:55AM EDT July 22, 2013), but don�� let this get you down.

  Advanced Cell Technology, Inc. previously reported the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company�� three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

• [By John Udovich]

  Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:

• [By CRWE]

  Today, ACTC surged (+1.96%) up +0.0014 at $.0730 with 1,679,139 shares in play thus far (ref. google finance Delayed: 12:31PM EDT July 26, 2013).

  Advanced Cell Technology, Inc. previously reported the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company�� three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

Hot Electric Utility Stocks To Buy For 2014: Advantage Oil & Gas Ltd (AAV)

Advantage Oil & Gas Ltd. and its subsidiaries engage in the acquisition, exploitation, development, and production of oil and gas in the provinces of Alberta and Saskatchewan, Canada. It produces and sells crude oil, natural gas, sulphur, and natural gas liquids primarily through marketing companies. As of February 5, 2013, the company�s core properties comprised of Glacier Montney natural gas asset with approximately 80 net sections of land located in Alberta. Advantage Oil & Gas Ltd. was founded in 2001 and is headquartered in Calgary, Canada.

Advisors' Opinion:

• [By Stephan Dube]

  Comparing the netbacks with its peers, we can see that MEG Energy reported Q2 operating netbacks of $41.93/Boe, Advantage Oil & Gas' (AAV) Q2 operating netbacks totaled $14.74/Boe, Baytex has realized $25.76/Boe for Q1 and Bonavista Energy operating netbacks for Q1 amounted to $19.49/Boe. Therefore, with an average netback of $26.11/Boe, BlackPearl's $28.65/Boe is a little higher than the average of its peers with higher realized prices and stronger recoveries.

• [By Eric Lam]

  Royal Bank gained 1.2 percent as the market value of the nation�� largest lender rose past C$100 billion for the first time. Bankers Petroleum Ltd. and Advantage Oil & Gas Ltd. (AAV) climbed more than 2.7 percent as oil companies advanced. H&R Real Estate Investment Trust and Canadian Apartment Properties REIT added at least 2.5 percent to pace gains among financial stocks. Athabasca Oil Corp. tumbled 9.9 percent after an Alberta court decided to allow an aboriginal group to appeal an approval of the company�� Dover oil-sands project.

Hot Electric Utility Stocks To Buy For 2014: GEO Group Inc (GEO)

The GEO Group, Inc., incorporated on April 5, 1988, specializes in the ownership, leasing and management of correctional, detention, and re-entry facilities and the provision of community-based services and youth services in the United States, Australia, South Africa, the United Kingdom and Canada. The Company operates in four segments: United States Corrections and Detention segment; GEO Community Services; International Services, and its Facility Construction and Design. The Company's United States Corrections and Detention segment primarily encompasses its United States-based privatized corrections and detention business. GEO Community Services segment consists of its community based services business, its youth services business and its electronic monitoring and supervision service. International Services segment primarily consists of its privatized corrections and detention operations in South Africa, Australia and the United Kingdom. Facility Construction and Design segment primarily contracts with various states, local and federal agencies for the design and construction of facilities for which the Company generally has been, or expects to be, awarded management contracts. In June 2013, it announced the closing of acquisition of the 1,287-bed Joe Corley Detention Center (the Center) in Montgomery County, Texas.

The Company owns, leases and operates a range of correctional and detention facilities, including maximum, medium and minimum security prisons, immigration detention centers, minimum security detention centers, and community based re-entry facilities. The Company offers counseling, education and /or treatment to inmates with alcohol and drugs abuse problems at most of the domestic facilities the Company manages. The Company is also a provider of compliance technologies, monitoring services, and evidence-based supervision and treatment programs for community-based parolees, probationers and pretrial defendants. On December 31, 2012, the Company divested its residential treatm! ent health care facility management contracts, (Residential Treatment Services (RTS)). Effective January 1, 2013, it began operating as a real estate investment trust (REIT). As of December 31, 2012, the Company's worldwide operations included the management and/or ownership of approximately 73,000 beds at 100 correctional, detention and residential facilities, including idle facilities, and also included the provision of monitoring services, tracking approximately 70,000 offenders on behalf of approximately 900 federal, state and local correctional agencies located in all 50 states. During the year ended December 31, 2012, the Company activated four new or expansion projects representing an aggregate of 2,082 additional beds.

The Company has an exclusive contract with the United States Immigration and Customs Enforcement, which the Company refers to as ICE, to provide supervision and reporting services designed to improves the participation of non-detained aliens in the immigration court system. The Company develops facilities based on contract awards, using its project development expertise and experience to design, construct and finance. The Company also provides secure transportation services for offender and detainee populations as contracted domestically and in the United Kingdom through its joint venture, GEO Amey PECS Ltd., which the Company refers to as GEOAmey. The Company provides a diversified scope of services on behalf of its government clients. Its correctional and detention management services involve the provision of security, administrative, rehabilitation, education, and food services, primarily at adult male correctional and detention facilities. Its community-based services involve supervision of adult parolees and probationers and the provision of temporary housing, programming, employment assistance and other services with the intention of the successful reintegration of residents into the community. The Company�� youth services include residential, detention and sh! elter car! e and community-based services along with rehabilitative and educational programs. The Company provides comprehensive electronic monitoring and supervision services. The Company provides secure transportation services for offender and detainee populations as contracted. Through the REIT subsidiaries (TRS) structure, a portion of the Company's businesses, which are non-real estate related, such as its managed-only contracts, international operations, electronic monitoring services, and other non-residential facilities, are part of wholly owned taxable subsidiaries of the REIT. Most of the Company's business segments, which are real estate related and involve company-owned and company-leased facilities, are part of the REIT.

The Company competes with Corrections Corporation of America; Management and Training Corporation; Louisiana Corrections Services, Inc.; Emerald Companies; Community Education Centers; LaSalle Southwest Corrections; Group 4 Securicor; Sodexo Justice Services (formerly Kaylx); Serco; G4 Justice Services, LLC; Elmo-Tech, a 3M Company, and Pro-Tech, a 3M Company

Advisors' Opinion:

• [By Tyler Laundon]

  And The GEO Group (GEO) is yet another compelling holding that most investors haven't heard of. The company operates correctional and detention facilities for various governments.

• [By Sean Williams]

  Corrections Corp. of America, also known as CCA, and GEO Group (NYSE: GEO  ) �are the two largest contracted prison companies. If there's any doubt that these companies are as good as gold, one need only look at CCA's first-quarter report from last week, which saw normalized funds from operations rise by a whopping 35% to $0.70 per share. CCA also boosted its full-year EPS from a range of $2.05-$2.15 to $2.08-$2.16.

• [By Sean Williams]

  The premise here would be that any increase in nationwide drug testing would be bound to turn up additional drug users and could boost the prison population. That would be great news for the GEO Group (NYSE: GEO  ) and Corrections Corp. of America (NYSE: CXW  ) , which are contracted out through the government to run and service prisons around the country.

Hot Electric Utility Stocks To Buy For 2014: Centor Energy Inc (CNTO)

Centor Energy Inc, formerly Centor, Inc., incorporated on February 16, 2011, is an exploration-stage company. The Company is engaged in the business of mineral exploration.

On November 26, 2012, the Company entered into a purchase agreement with Bullnet Gold Resources Limited. As of May 31, 2013, the Company had not generated revenues. As of May 31, 2013, the Company had no mining operations.

Advisors' Opinion:

• [By John Udovich]

  While Bakken formation oil and gas stocks have grabbed the attention of�American investors, small cap Alberta or Saskatchewan oil and gas stocks Advantage Oil & Gas Ltd (NYSE: AAV), Sonde Resources Corp (NYSEMKT: SOQ) and up and coming Centor Energy Inc (OTCBB: CNTO) have been largely overlooked as they seek to exploit oil and gas (including oil sands) in the resource rich Canadian provinces of Alberta or Saskatchewan or seek strategic alternatives for their assets in these areas or themselves. It should be mentioned that Canada�� oil reserves are third only to Venezuela and Saudi Arabia with over 95% of these reserves being the oil sands of Alberta plus that province contains much of the country�� conventional oil reserves as well. In addition, the province of Saskatchewan along with offshore areas of Newfoundland contain substantial production and reserves. Excluding oil sands, Alberta would have 39% of Canada�� remaining conventional oil reserves,�followed by�offshore Newfoundland with�28% and Saskatchewan with 27%.

Hot Electric Utility Stocks To Buy For 2014: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors' Opinion:

• [By Ben Levisohn]

  That would be Amgen (AMGN), which fell 1.4% today,� Biogen Idec (BIIB), which dropped 5.1%, Celgene�(CELG), which declined 2.1%, Gilead Sciences (GILD), which dropped 4%, Regeneron Pharmaceuticals (REGN), which fell 3.8%, and Alexion Pharmaceuticals (ALXN), which finished off 1.1%.

• [By Mani]

  Biogen Idec Inc (NASDAQ:BIIB) has been outperforming for several years from the strength of its multiple sclerosis (MS) treatments -- Tecfidera and Tysabri. Now, the focus is starting to move to BIIB's burgeoning pipeline to sustain, and potentially accelerate growth beyond 2014.

• [By Ben Levisohn]

  Shares of Regeneron Pharmaceuticals (REGN) have fallen 4.4% to $323.62 at 3:23 p.m., while�Biogen�(BIIB) has dropped 4% to $327.04 and�Gilead Sciences (GILD) has dipped 0.4% to $79.58. The iShares Nasdaq Biotechnology Index ETF�(IBB), meanwhile, has dropped 0.9% to $258.85 and the SPDR S&P Biotech ETF�(XBI) has declined 0.6% to $160.69. Suffice it to say, biotech investors don’t appear to be enjoying zero-G nearly as much as Kate Upton.